A significant increase in the plasma IL-22 levels of RCC patients compared with healthy controls was also observed (27.38 ± 0.75 pg/mL vs. 20.06 ± 0.54 pg/mL ***P<0.001; Fig. 2B). This evidence concerns the gene IL22 and renal cell carcinoma.